Quick Answer
ABVC BIOPHARMA, INC. reported Cash and Equivalents of $681.5 thousand for fiscal year 2025.
ABVC BIOPHARMA, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $681.5K | +174.4% |
| 2024 | $248.4K | +312.9% |
| 2023 | $60.2K | -29.4% |
| 2022 | $85.3K | -98.5% |
| 2021 | $5.83M | +36.4% |
| 2020 | $4.27M | +2861.4% |
| 2019 | $144.3K | -36.3% |
| 2018 | $226.7K | +142.9% |
| 2017 | $93.3K | -54.4% |
| 2017 | $204.9K | +998.7% |
| 2016 | $18.6K | -89.3% |
| 2016 | $173.5K | -82.6% |
| 2015 | $994.8K | — |
| 2014 | $0.00 | -100.0% |
| 2013 | $618.00 | -95.4% |
| 2012 | $13.4K | -81.4% |
| 2011 | $71.8K | +2451.0% |
| 2010 | $2.8K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $192.1K | +39.8% | -50.5% |
| June 30, 2025 | $388.3K | +212.4% | +155.1% |
| March 31, 2025 | $152.2K | +399.2% | -38.7% |
| December 31, 2024 | $248.4K | +312.9% | +80.8% |
| September 30, 2024 | $137.3K | — | +10.5% |
| June 30, 2024 | $124.3K | +25.2% | +307.7% |
| March 31, 2024 | $30.5K | -97.3% | -49.3% |
| December 31, 2023 | $60.2K | -29.4% | -39.4% |
- ABVC BIOPHARMA, INC. showed an increase of +174.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, ABVC BIOPHARMA, INC.’s cash and equivalents has grown by 24117.5% (from $2.8 thousand to $681.5 thousand).
- The most recent figure is from ABVC BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: